Key result
Low-dose alteplase yields mixed survival outcomes in pregnant patients with intermediate-risk PE.
Why the study?
Managing intermediate- to high-risk pulmonary embolism during pregnancy is challenging because evidence regarding thrombolytic therapy in this population is limited.
Does systemic thrombolysis (including low-dose alteplase) or anticoagulation improve maternal and fetal outcomes in pregnant women with intermediate-risk pulmonary embolism?
Case Report (n=3)
No
Does systemic thrombolysis (including low-dose alteplase) or anticoagulation improve maternal and fetal outcomes in pregnant women with intermediate-risk pulmonary embolism?
This three-case series suggests that reduced-dose systemic thrombolysis (50 mg alteplase) may be a viable individualized treatment option for pregnant patients with intermediate-risk pulmonary embolism who deteriorate or have persistent right ventricular dysfunction despite anticoagulation.
Answers are grounded in this paper and cite their sources.
Requires cautious individualized management in pregnant PE; leaves open optimal anticoagulation or thrombolysis strategies.
Pulmonary embolism (PE) remains a major cause of maternal morbidity and mortality during pregnancy, and management of intermediate- to high-risk PE remains particularly challenging due to the limited evidence regarding thrombolytic therapy in this population. We report three cases of pregnancy-associated intermediate-risk PE managed at a tertiary referral center between 2020 and 2024. All patients had imaging-confirmed PE with right ventricular (RV) dysfunction and elevated cardiac biomarkers. A 31-year-old woman at 11 weeks’ gestation initially improved with anticoagulation but subsequently developed sudden cardiac arrest and underwent rescue systemic thrombolysis during cardiopulmonary resuscitation without successful recovery. A 38-year-old woman with underlying gastrointestinal stromal tumor was managed conservatively with anticoagulation alone because of high bleeding risk and had favorable maternal and fetal outcomes. A third patient at 13 weeks’ gestation demonstrated persistent hypoxemia, tachycardia, and RV dysfunction despite anticoagulation and was successfully treated with low-dose alteplase (50 mg), resulting in marked clinical and echocardiographic improvement without maternal or fetal complications. These cases highlight the complexity of therapeutic decision-making in pregnant women with intermediate-risk PE. In selected patients with persistent right ventricular dysfunction or clinical deterioration despite anticoagulation, reduced-dose systemic thrombolysis may be considered as an individualized therapeutic strategy within a multidisciplinary management framework.
No takes yet. Share an insight, caveat, or question.
Naderi et al. (2026) conducted a case report in Pregnancy-associated intermediate- to high-risk pulmonary embolism (n=3). Systemic thrombolysis (including low-dose alteplase) and anticoagulation vs. Anticoagulation alone was evaluated on Maternal and fetal survival and clinical recovery.
Synapse has enriched 10 related papers. Consider them for comparative context: